DRUG · Unmapped registry intervention
Carbo/cyclo
Find medicine records ·
Find other trials using this name
Clinical trial
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Carbo/cyclo + atezolizumab
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Paclitaxel + Atezolizumab
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTriple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
Carbo/cycloDRUG
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
The Netherlands Cancer Institutelead sponsor
Borstkanker Onderzoek Groepcollaborator
Roche Pharma AGcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01898117 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.